Most recent articles first.
Note that some of these articles are inaccurate.
Fluvoxamine basically is like pouring water on a fire.
- It is not just for lungs. It benefits your whole body including and especially protecting your brain from permanent injury.
- It is not just for treating early disease. It can be used at any stage. But giving it early will prevent long haul COVID.
- It does not just stop progression of COVID. It reverses it. Most people feel better in 24 hours and when given sufficiently early can be back to normal in 3 days.
- My advocacy for fluvoxamine is not based just on the Phase 2 trial. It is based on the numerous sources of data all positive including research, observational studies, randomized studies, and real life results from hundreds of patients. See Why the FDA should grant an EUA for Fluvoxamine. There is not a drug with better results that we know about (except for proxalutamide).
In general, whatever your COVID stage, fluvoxamine has been shown to reverse the inflammation; the sicker you are, the longer it takes. It has even been shown to work if you are intubated and only days away from death.
The caveats on the drug include drug interactions, mental state, and that it enhances caffeine (so avoid coffee while taking the drug). Because the drug is only used for a short duration, it can safely be used even if you are pregnant.
Fluvoxamine can be prescribed now off-label using a process known as "shared decision making."
Television stories
Story updated March 23, 2021

60 Minutes did extensive reporting on fluvoxamine (air date March 7, 2021):

60 Minutes overtime interview with Francis Collins:
CNN's Dr. Sanjay Gupta did a story on repurposed drugs featuring fluvoxamine. On Feb 27, it was the lead story on both the CNN website and mobile app.


Dr. Oz COVID-19 minute on fluvoxamine:
The NBC story on fluvoxamine is short but very well done and extremely compelling:
Featured on Dr. Oz on Feb 19, 2021 (25,317 views)
The NBC story on fluvoxamine is short but very well done and extremely compelling:



Tweets
Forgotten Fluvoxamine Friday With Steve Kirsch’s @stkirsch (1st Interview) that changed my Covid-19 Longhauler Life. #DoseOfDrDrew https://t.co/HKIMwAFQMm
— Dr. Drew (@drdrew) February 27, 2021
Internet videos
Interview on fluvoxamine
The case for fluvoxamine in just 15 minutes:
Steve Kirsch talks about fluvoxamine:
Anne DeGheest talks about fluvoxamine here starting at 2:30. She knew Dr. Seftel when she was at Harvard.
Dr. Larry Brilliant, a world famous epidemiologist, talking about fluvoxamine on Dr. Drew (watch at 7:00):
DrBeen video explaining how fluvoxamine works
Fluvoxamine - Important for Long Haulers - Reduced Clinical Deterioration in COVID https://t.co/hEDAqTDMbu
— drbeen medical (@drbeen_medical) February 11, 2021
A superb presentation given by Dr. Christy Risinger
Fascinating 1 hour talk by Farid Jalali on COVID, platelets, serotonin, SSRIs, and cyproheptadine:
December 22, 2020: Vikas Sukhatme, Dean of the Emory Medical School, calls for the use of fluvoxamine off-label using "shared decision making"

Print stories
IEEE Spectrum, March 31, 2021
Optical Mouse Inventor Hunts for a Covid Cure—and May Have Found One
Kaiser Health News, March 29, 2021

Los Altos Hills Town Crier, March 17, 2021

USA Today, March 14
March 12, 2021 Inverse talks about the fact fluvoxamine is a potent FIASMA:
A SURPRISING TREATMENT FOR COVID-19 COULD BE THE KEY TO STOPPING VARIANTS
March 11, People's Pharmacy:

Feb 3, 2021: Front page Los Angeles Times








Op-eds


One of the members of the Wall St. Journal editorial board wrote an op-ed on the importance of repurposed drugs and made prominent mention of fluvoxamine and concludes with: "Don’t let the perfect be the enemy of progress." Well said!
TrialSiteNews had suggestions to Vikas's op-ed

A wonderful op-ed by Vikas Sukhatme in Health Affairs on how to do drug testing in a pandemic which lists fluvoxamine as the top drug to look at:

Op-ed written by former members of Biden's COVID task force

Op-ed written by Dr. Jeffrey Klausner published in the Washington Post recommending shared decision making and disclosing in public for the first time that an expert panel reviewed the fluvoxamine data on Jan 22, and then voted >2:1 in favor of supporting fluvoxamine for shared decision making.



Technical papers






